However, we previously demonstrated that the SphK2 inhibitor ABC294640 impedes disease progression in a xenograft model of Ph− human ALL, suggesting that SphK2 loss/inhibition has some effect on disease progression [30]. This evidence concerns the gene SPHK2 and acute lymphoblastic leukemia.